Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;184(4):731-739.
doi: 10.1111/bjd.19346. Epub 2020 Sep 16.

A 10-year review of surgical management of dermatofibrosarcoma protuberans

A Durack  1 , S Gran  2 , M D Gardiner  3   4 , A Jain  3   5 , E Craythorne  6 , C M Proby  7 , J Marsden  8 , C A Harwood  9 , R N Matin  10 ; DFSP Collaborators
Collaborators, Affiliations
Review

A 10-year review of surgical management of dermatofibrosarcoma protuberans

A Durack et al. Br J Dermatol. 2021 Apr.

Abstract

Background: Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Standard treatment in the UK is either wide local excision (WLE) or Mohs micrographic surgery (MMS). It is unclear which approach has the lower recurrence rate.

Objectives: We undertook a retrospective comparative review of surgical management of DFSP in the UK National Health Service in order to define (i) current surgical practice for primary and recurrent DFSP, (ii) local recurrence rates for primary DFSP and (iii) survival outcomes for DFSP.

Methods: A retrospective clinical case-note review of patients with histologically confirmed DFSP (January 2004 to December 2013) who have undergone surgical treatment.

Results: The surgical management of 483 primary and 64 recurrent DFSP in 11 plastic surgery and 15 dermatology departments was analysed. Almost 75% of primary DFSP (n = 362) were treated with WLE and 20% (n = 97) with MMS. For recurrent DFSP, 69% (n = 44) and 23% (n = 15) of patients underwent WLE and MMS, respectively. Recurrent primary DFSP occurred in six patients after WLE and none after MMS. The median follow-up time was 25·5 months (interquartile range 6·8-45·1) for new and 19·8 (IQR 4·5-44·5) for recurrent DFSP [Correction added on 1 Feb 2021, after first online publication: 4.8 years (interquartile range 3.5-5.8) was incorrect], with eight reported deaths during the follow-up analysis period (one confirmed to be DFSP related).

Conclusions: WLE was the most common surgical modality used to treat DFSP across the UK. The local recurrence rate was very low, occurring only after WLE. Although a prospective randomized controlled trial may provide more definitive outcomes, in the absence of a clearly superior surgical modality, treatment decisions should be based on patient preference, clinical expertise and cost.

PubMed Disclaimer

Comment in

References

    1. Kreicher KL, Kurlander DE, Gittleman HR et al. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg 2016; 42 (Suppl. 1):S24-31.
    1. Akram J, Wooler G, Lock-Andersen J. Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines. J Plast Surg Hand Surg 2014; 48:67-73.
    1. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007; 56:968-73.
    1. National Cancer Registration and Analysis Service. Non-melanoma skin cancer in England, Scotland, Northern Ireland, and Ireland. Available at: http://www.ncin.org.uk/publications/data_briefings/non_melanoma_skin_can... (last accessed 3 July 2020).
    1. Ratner D, Thomas CO, Johnson TM et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997; 37:600-13.

Publication types